Pharmacokinetics and Side Effects of Δ9-Tetrahydrocannabinol and Cannabidiol in Patients with Different Stages of CKD
Total exposure to THC, CBD, and metabolites was higher in patients with CKD stages 4 and 5 compared with controls, and side effects may be more pronounced; however, the intersubject variability was high. If cannabis products are administered to patients with severe CKD, caution is needed.
Authors
- Dinah Sherzad Khatir (ORCID: https://orcid.org/0009-0008-9535-4587)
- Krista Dybtved Kjærgaard
- Charlotte Uggerhøj Andersen (ORCID: https://orcid.org/0000-0003-0543-6519)
- Jørgen Bo Hasselstrøm (ORCID: https://orcid.org/0000-0002-5928-9238)
- Eva Aggerholm Sædder (ORCID: https://orcid.org/0000-0003-4905-1004)
- Lambert K. Sørensen (ORCID: https://orcid.org/0000-0002-4262-0035)
- Marie Bach Sønderskov (ORCID: https://orcid.org/0009-0009-4593-8573)
Institutions
- Aarhus University (DK)
- Aarhus University Hospital (DK)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2024-12-30
- DOI
- https://doi.org/10.1016/j.ekir.2024.12.030
- Citations
- 3
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 1.34
Funders
- Aarhus Universitet
- Aarhus Universitetshospital